Isabel T. Rubio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Isabel T. Rubio has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jordi Xercavins
Autonomous University of Barcelona
3 shared publications - Martín Espinosa-Bravo
Breast Surgical Oncology, Breast Cancer Center, Hospital Universitario Vall d'Hebron, Barcelona, Spain
2 shared publications - Vicente Peg
Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
2 shared publications - Antonio Esgueva
Breast Surgical Oncology, Clínica Universidad de Navarra, Madrid, Universidad de Navarra, Spain
1 shared publication Antonio J Esgueva
Hospital Universitario Vall d´Hebron, Barcelona, Spain
1 shared publicationCarme Merced
Breast Section, Breast Cancer Center, Hospital Universitario Vall d'Hebron, Barcelona, Spain Department of Pathology, Hospital Universitario Vall d'Hebron, Barcelona, Spain
1 shared publication
Latest Publications
- 1 October 2014
- Published by Elsevier in Clinical Breast Cancer
- Vol. 14 (5) , 346-351
Breast-Conservative Surgery Followed by Radiofrequency Ablation of Margins Decreases the Need for a Second Surgical Procedure for Close or Positive Margins
- 1 October 2014
- Published by Elsevier in Clinical Breast Cancer
- Vol. 14 (5) , 346-351
Breast-Conservative Surgery Followed by Radiofrequency Ablation of Margins Decreases the Need for a Second Surgical Procedure for Close or Positive Margins
- 10 September 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (26) , 100
Increased detection of sentinel nodes in breast cancer patients with the use of superparamagnetic iron oxide tracer.
100 Background: The use of superparamagnetic iron oxide (SPIO) tracer for sentinel node biopsy (SLN) has shown non inferiority compared with the radioisotope technique in early breast cancer. False negative rates of SLN biopsy after neoadjuvant treatment (NAC) have decreased with dual tracer (radioisotope/dye) and with the excision of > 2 SLNs. This study was designed to evaluate the outcome of SLN after NAC using a dual tracer (SPIO-Tc99) and to compare it with the SLN by same dual tracer in the adjuvant setting. Methods: Between July 2013 and March 2014, 30 patients with invasive breast cancer (IBC) and SLN biopsy after NAC (NAC- SLN), and 118 patients with IBC not treated with NAC (adjuvant SLN), whose SLN was traced by Tc99 and SPIO were included in the study. Patients were injected subareolar with Tc99 the day before surgery and with the SPIO intraoperatively. SLN was excised if it was radioactive, magnetic or palpable. Patients signed an inform consent. Results: Detection rate by Tc 99 was successful in 113 (95.7%) patients and by SPIO in 116 (98.3%) in the adjuvant SLN (P= 0.0833) while in the NAC-SLN group detection rate by Tc-99 was successful in 28 patients (93.3%) and by SPIO in 30 patients (100%) (P =0.1573). Concordance rates per patient in the adjuvant SLN between techniques was 98.2%, while in the NAC-SLN was 100%. (p = 0.4762) Mean number of SLNs excised by 99Tc and SPIO were 1.9 and 2.21 respectively in the adjuvant SLN, (p=0.001) while 1.533 and 2.60 respectively in the NAC-SLN group. (p=0.0016) In the adjuvant SLN, the SLN was positive in 36 patients (30%), and in the NAC-SLN in 9 patients (30%). In the adjuvant SLN, both techniques detected same number of positive nodes but in the NAC-SLN, 9 patients had a positive SLN by SPIO (> 2 SLNs by SPIO and 1 SLN by Tc99) and 7 patients had a positive SLN by Tc99. Conclusions: Detection of SLNs with SPIO allows for easy identification of axillary nodes and can be used to reliably identify SLNs in breast cancer. Even though the small sample size in the NAC-SLN, the higher number of SLNs excised by the SPIO may optimize the success of SLN after NAC.
- 10 September 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (26) , 100
Increased detection of sentinel nodes in breast cancer patients with the use of superparamagnetic iron oxide tracer.
100 Background: The use of superparamagnetic iron oxide (SPIO) tracer for sentinel node biopsy (SLN) has shown non inferiority compared with the radioisotope technique in early breast cancer. False negative rates of SLN biopsy after neoadjuvant treatment (NAC) have decreased with dual tracer (radioisotope/dye) and with the excision of > 2 SLNs. This study was designed to evaluate the outcome of SLN after NAC using a dual tracer (SPIO-Tc99) and to compare it with the SLN by same dual tracer in the adjuvant setting. Methods: Between July 2013 and March 2014, 30 patients with invasive breast cancer (IBC) and SLN biopsy after NAC (NAC- SLN), and 118 patients with IBC not treated with NAC (adjuvant SLN), whose SLN was traced by Tc99 and SPIO were included in the study. Patients were injected subareolar with Tc99 the day before surgery and with the SPIO intraoperatively. SLN was excised if it was radioactive, magnetic or palpable. Patients signed an inform consent. Results: Detection rate by Tc 99 was successful in 113 (95.7%) patients and by SPIO in 116 (98.3%) in the adjuvant SLN (P= 0.0833) while in the NAC-SLN group detection rate by Tc-99 was successful in 28 patients (93.3%) and by SPIO in 30 patients (100%) (P =0.1573). Concordance rates per patient in the adjuvant SLN between techniques was 98.2%, while in the NAC-SLN was 100%. (p = 0.4762) Mean number of SLNs excised by 99Tc and SPIO were 1.9 and 2.21 respectively in the adjuvant SLN, (p=0.001) while 1.533 and 2.60 respectively in the NAC-SLN group. (p=0.0016) In the adjuvant SLN, the SLN was positive in 36 patients (30%), and in the NAC-SLN in 9 patients (30%). In the adjuvant SLN, both techniques detected same number of positive nodes but in the NAC-SLN, 9 patients had a positive SLN by SPIO (> 2 SLNs by SPIO and 1 SLN by Tc99) and 7 patients had a positive SLN by Tc99. Conclusions: Detection of SLNs with SPIO allows for easy identification of axillary nodes and can be used to reliably identify SLNs in breast cancer. Even though the small sample size in the NAC-SLN, the higher number of SLNs excised by the SPIO may optimize the success of SLN after NAC.
- 24 May 2014
- Published by Wiley in Journal of Surgical Oncology
- Vol. 110 (1) , 1
Breast conservative surgery in breast cancer: Simple can be harder than complex
- 24 May 2014
- Published by Wiley in Journal of Surgical Oncology
- Vol. 110 (1) , 1
Breast conservative surgery in breast cancer: Simple can be harder than complex
- 18 January 2012
- Published by Wiley in Journal of Surgical Oncology
- Vol. 106 (1) , 89-93
Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer
Background: The axillary reverse mapping (ARM) technique has been proposed to prevent arm lymphedema. We conducted this study to assess the feasibility of the technique and the outcomes of patients with neoadjuvant chemotherapy (NAC).Methods: From July 2009 to May 2010, a prospective study was performed in 36 patients with breast cancer undergoing an ALND. The ARM technique was performed injecting 3 cm3 of Patent Blue in the ipsilateral arm. Of the 36 patients, 29 patients received NAC previously to the ARM and 7 patients had an ALND and ARM performed as first treatment for positive axillary nodes.Results: The identification rate of blue nodes was 83.3% (30 patients). Sentinel lymph node (SLN) was performed in 15 of 29 (42%) patients in the NAC group. Of these 15, two patients (13%) had a concordance between the blue and the hot node. Blue nodes were positive in 4 (13%) of the 30 patients.Conclusions: The ARM technique is feasible in patients undergoing NAC. Patients with extensive nodal involvement have increased risk of having positive blue nodes. More studies are needed to assess the subgroup of patients with positive axilla that may have the blue node spared without compromising the oncological treatment. J. Surg. Oncol. 2012; 106:89–93.
- 18 January 2012
- Published by Wiley in Journal of Surgical Oncology
- Vol. 106 (1) , 89-93
Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer
Background: The axillary reverse mapping (ARM) technique has been proposed to prevent arm lymphedema. We conducted this study to assess the feasibility of the technique and the outcomes of patients with neoadjuvant chemotherapy (NAC).Methods: From July 2009 to May 2010, a prospective study was performed in 36 patients with breast cancer undergoing an ALND. The ARM technique was performed injecting 3 cm3 of Patent Blue in the ipsilateral arm. Of the 36 patients, 29 patients received NAC previously to the ARM and 7 patients had an ALND and ARM performed as first treatment for positive axillary nodes.Results: The identification rate of blue nodes was 83.3% (30 patients). Sentinel lymph node (SLN) was performed in 15 of 29 (42%) patients in the NAC group. Of these 15, two patients (13%) had a concordance between the blue and the hot node. Blue nodes were positive in 4 (13%) of the 30 patients.Conclusions: The ARM technique is feasible in patients undergoing NAC. Patients with extensive nodal involvement have increased risk of having positive blue nodes. More studies are needed to assess the subgroup of patients with positive axilla that may have the blue node spared without compromising the oncological treatment. J. Surg. Oncol. 2012; 106:89–93.
- 2 June 2011
- Published by Hindawi Limited in The Breast Journal
- Vol. 17 (4) , 420-421
Breast Metastasis from Rhabdomyosarcoma of the Nasal Septum in a Pregnant Adult Woman
- 2 June 2011
- Published by Hindawi Limited in The Breast Journal
- Vol. 17 (4) , 420-421
Breast Metastasis from Rhabdomyosarcoma of the Nasal Septum in a Pregnant Adult Woman